HONG KONG – In back-to-back deals involving a total of $735 million in up-front cash, French pharma major Sanofi SA is collecting more diabetes drugs for its pipeline, aiming to mitigate the impact on its diabetes business, which has seen a 6.6 percent decline in the global market.
HONG KONG – In a deal that is likely to open the door of the Chinese and global market to an early stage South Korean drug developer, 3Sbio Inc (HK:2530) signed an exclusive agreement to develop, manufacture and market an antibody-drug conjugate (ADC) that targets the HER2 pathway for cancer. The deal with Alteogen Inc. (KS:196170), of Daejeon, South Korea, covers Mainland China, Hong Kong and Macau and includes an undisclosed up-front payment as well as further milestone payments and royalties for the development of ALT-P7.
HONG KONG – In a deal that is likely to open the door of the Chinese and global market to an early stage South Korean drug developer, 3Sbio Inc (HK:2530) signed an exclusive agreement to develop, manufacture and market an antibody drug conjugate (ADC) that targets the HER2 pathway for cancer.
